Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3KN2Q)

• Drug Name: GI-270384X Drug Info
• Synonyms: 270384

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DM3KN2Q

Molecule-Related Drug Atlas

Drug(s) Targeting Intercellular adhesion molecule ICAM-1 (ICAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
lifitegrast	DM4WVC5	Dry eye disease	9E1Z	Approved	[2]
Alicaforsen	DMQ509J	Lleum inflammation	1A40.0	Phase 3	[3]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[4]
APC-8015F	DM3VP19	Prostate cancer	2C82.0	Phase 2	[5]
AIC100	DMSPBOW	Thyroid cancer	2D10	Phase 1	[6]
A-252444.0	DMDTA36	Inflammation	1A00-CA43.1	Terminated	[7]
MOR-102	DMRCH1M	Psoriasis vulgaris	EA90	Terminated	[8]
ISIS-1939	DMGN4OQ	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[10]
GMI-1271	DMDTGWQ	Acute myeloid leukaemia	2A60	Phase 3	[11]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[12]
Bimosiamose	DM0TH9A	Atopic dermatitis	EA80	Phase 2a	[13]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[14]
PF-07209326	DM7YRAL	Sickle-cell disorder	3A51	Phase 1	[15]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[16]
O-Sialic Acid	DMCAR7B	Discovery agent	N.A.	Investigative	[17]
Efomycine M	DMOKX76	Discovery agent	N.A.	Investigative	[18]
1na	DM0A1YI	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E-selectin (SELE)	TTAU4D6	LYAM2_HUMAN	Modulator	[1]
Intercellular adhesion molecule ICAM-1 (ICAM1)	TTCT6F7	ICAM1_HUMAN	Modulator	[1]

References

• [1] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [2] Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
• [5] National Cancer Institute Drug Dictionary (drug id 561410).
• [6] Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
• [8] Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66.
• [9] Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71.
• [10] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [11] Clinical pipeline report, company report or official report of glycomimetics.
• [12] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [13] Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
• [14] Clinical pipeline report, company report or official report of GlycoMimetics.
• [15] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [17] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [18] Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.